Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-15 R alpha

IL-15 R alpha

Brief Information

Name:Interleukin-15 receptor subunit alpha
Target Synonym:Interleukin 15 Receptor Alpha Isoform IC2,Interleukin 15 Receptor Alpha Isoform IC8,Interleukin 15 Receptor Alpha Isoform EM2,Interleukin-15 Receptor Subunit Alpha,Interleukin 15 Receptor Alpha Isoform IC4,Interleukin 15 Receptor Alpha Isoform IC5,Interleukin 15 Receptor Alpha Isoform IC7,IL15RA,CD215,IL-15RA,IL-15 Receptor Subunit Alpha,CD215 Antigen,Interleukin 15 Receptor Subunit Alpha,Interleukin 15 Receptor Alpha Isoform IC6,Interleukin 15 Receptor, Alpha,Interleukin 15 Receptor Alpha Isofo
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

ILA-H5253-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-15 R alpha, Fc Tag (Cat. No. ILA-H5253) inhibits IL-15-dependent proliferation of CTLL-2 cells. The ED50 for this effect is 2.77-4.20 ng/mL (Routinely tested).

Mouse IL-15 R alpha, Fc TagMouse IL-15 R alpha, Fc Tag (Cat. No. ILA-M5253) ELISA bioactivity

Immobilized Human IL-15, premium grade (Cat. No. IL5-H4117) at 5 μg/mL (100 μL/well) can bind Mouse IL-15 R alpha, Fc Tag (Cat. No. ILA-M5253) with a linear range of 0.6-10 ng/mL (QC tested).

FITC-Labeled Human IL-15 R alpha, Fc Tag (Cat. No. ) MALS images

The purity of FITC-Labeled Human IL-15 R alpha, Fc Tag (Cat. No. ILA-HF255) is more than 85% and the molecular weight of this protein is around 115-140 kDa verified by SEC-MALS.

FITC-Labeled Human IL-15 R alpha, Fc TagFITC-Labeled Human IL-15 R alpha, Fc Tag (Cat. No. ILA-HF255) ELISA bioactivity

Immobilized Human IL-15, His Tag (Cat. No. IL5-H52H8) at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human IL-15 R alpha, Fc Tag (Cat. No. ILA-HF255) with a linear range of 0.078-5 μg/mL (QC tested).

Synonym Name

IL-15 R alpha,CD215,IL15RA,IL-15RA,IL-15R-alpha


IL15R is a heterotrimer of IL15RA, IL2RB and IL2RG. IL-15RA, also known as CD215, IL-15 R alpha, is a widely expressed 60 kDa transmembrane glycoprotein. High-affinity receptor for interleukin-15. Can signal both in cis and trans where IL15R from one subset of cells presents IL15 to neighboring IL2RG-expressing cells. Expression of different isoforms may alter or interfere with signal transduction. An interleukin (IL)-15 superagonist/IL-15 receptor α fusion complex (IL-15SA/IL-15RA; ALT-803) activates the IL-15 receptor on CD8 T cells and NK cells, and has shown significant anti-tumor. Signal transduction involves SYK. Higher levels of soluble sIL-15RA form in comparison with membrane-bound forms is present in all brain structures.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
QL-415 QL-415 Phase 1 Clinical Neoplasms Details
Recombinant human interleukin 15(Beijing Kawin) Phase 1 Clinical Beijing Kawin Technology Share-Holding Co Ltd Solid tumours Details
VG-201 VG-201 Phase 1 Clinical ViroGin Biotech Ltd Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
PF-07209960 PF-07209960 Phase 1 Clinical Pfizer Inc Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung Details
OXS-3550 OXS-3550-TriKE; GTB-3550; OXS-3550; OXIS-3550; 161533-TriKE; 161533 TriKE Oxis Biotech, University Of Minnesota Details
Heterodimeric interleukin 15(Novartis Pharma) NIZ-985 Novartis Pharma Ag Details
ASKG-315 ASKG-215β; ASKG-315; ASKG-215b Phase 1 Clinical Askgene Pharma Solid tumours; Neoplasms Details
RTX-240 RTX-240 Phase 2 Clinical Rubius Therapeutics Inc Leukemia, Promyelocytic, Acute Details
KD-033 KD-033 Phase 1 Clinical Takeda Pharma Solid tumours Details
XmAb24306 XmAb-24306; RG-6323; RO-7310729; XmAb-306 Phase 1 Clinical Genentech Inc, Xencor Inc Solid tumours; Neoplasms; Multiple Myeloma Details
BJ-001(Boji Biomedical Technology) BJ-001 Phase 1 Clinical Boji Biomedical Technology (Hangzhou) Co Ltd Solid tumours; Communicable Diseases; Neoplasm Metastasis Details
PD-L1 t-haNK cell therapy/Inbakicept/Aldoxorubicin Hydrochloride(Immunitybio) Phase 2 Clinical Immunitybio Inc Pancreatic Neoplasms Details
SHR-1501 SHR-1501 Phase 2 Clinical Jiangsu Hengrui Medicine Co Ltd Neoplasms; Urinary Bladder Neoplasms Details
NKTR-255 NKTR-255 Phase 2 Clinical Nektar Therapeutics Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Multiple Myeloma; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Lung Neoplasms; Uterine Cervical Neoplasms Details
Nanrilkefusp alfa RLI-15; CYP-0150; SOT-101; SO-C101 Phase 2 Clinical Sotio Mesothelioma; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Thymus Neoplasms; Colorectal Neoplasms; Prostatic Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Thyroid Diseases; Prostatic Neoplasms, Castration-Resistant; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Carcinoma, Merkel Cell; Anus Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Ovarian Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message